Phase II success in HCC for c-MET inhibitor as monotherapy
19 January 2012
Sukaina Virji
Please Login to read the full article.
19 January 2012
Sukaina Virji
sukaina.virji@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- ArQule expects $48.7M from offering as it advances c-MET inhibitor tivantinib
- AVEO's unconvincing Phase II ficlatuzumab data point to need for further studies
- Roche/Plexxikon's Zelboraf secures EU approval for personalised skin cancer medicine
- Transgene and Jenner begin liver cancer trial for enclitic therapy
ANALYSIS
Other Informa Analysis
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
